Doctaverse

Childhood Polyarteritis Nodosa: A Clinician's Monograph

Clinician reference on childhood polyarteritis nodosa — EULAR/PRINTO/PRES Ankara 2008 criteria, systemic vs cutaneous PAN, the DADA2 differential, red flags, and management strategy.

Full criteria: Pediatric-Onset Polyarteritis Nodosa.

Definition and epidemiology

Polyarteritis nodosa (PAN) is a necrotising vasculitis of small- and medium-sized arteries with aneurysm formation and segmental, focal involvement that spares the smallest vessels (no glomerulonephritis, no capillaritis). It is rare in childhood, with a roughly equal sex distribution and a mean onset around 9 years. Two principal phenotypes are recognised: systemic PAN and the milder, skin-limited cutaneous PAN, the latter often relapsing and frequently post-streptococcal.

A critical modern caveat: monogenic mimics — particularly DADA2 (deficiency of adenosine deaminase 2) — can present as early-onset PAN-like vasculitis with livedo, strokes, and immunodeficiency. Hepatitis B-associated PAN, historically common, is now rare where vaccination is widespread.

Clinical features

PAN is a multisystem disease driven by ischaemia. Constitutional symptoms (fever, weight loss, malaise) are near-universal. Organ-specific features include:

Cutaneous PAN is confined to skin, muscle, and joints with no progressive visceral involvement.

Diagnosis

There is no single confirmatory test. Diagnosis rests on a compatible clinical picture plus histology (necrotising arteritis of medium/small vessels) OR angiographic abnormalities (aneurysms, stenoses, occlusions) of medium-sized arteries — one of which is mandatory under the validated EULAR/PRINTO/PRES (Ankara 2008) criteria. Supportive items include skin involvement, myalgia/muscle tenderness, hypertension, peripheral neuropathy, and renal involvement. The criteria perform at ~89.6% sensitivity and ~99.6% specificity. ANCA is characteristically negative — a positive ANCA should redirect toward ANCA-associated vasculitis. Always screen for hepatitis B and, in early-onset or familial disease, ADA2 activity/gene testing.

See the full criteria: Pediatric-Onset Polyarteritis Nodosa

Red flags

Management overview

Treatment is risk-stratified by disease severity and organ involvement (drug classes/strategy only):

Manage hypertension aggressively, provide thrombosis risk assessment, and follow per SHARE recommendations with pediatric rheumatology. Prognosis has improved markedly with modern therapy, though relapse is common.

References

  1. Ozen S, et al. EULAR/PRINTO/PRES Ankara 2008 criteria, Part II. Ann Rheum Dis. 2010;69:798-806.
  2. de Graeff N, et al. SHARE recommendations for rare paediatric vasculitides. Rheumatology. 2019;58:656-671.
  3. Nelson Textbook of Pediatrics, 21st ed.

Decision support for qualified clinicians only — verify against current primary guidelines and your clinical judgement.

Get the Doctaverse app

Use the calculators, diagnostic criteria and drug formulary at the bedside.

Google Play App Store Run the diagnostic

References

Last updated 2026-06-28.

More like this

Abdominal Migraine in Children: A Clinician's Monograph

Clinician reference on pediatric abdominal migraine — Rome IV criteria, the stereotyped paroxysmal pattern, red flags that mandate workup, and management.

Allergic Bronchopulmonary Aspergillosis: A Clinician's Monograph

Clinician reference on ABPA in children — ISHAM/Rosenberg-Patterson criteria, the asthma and cystic fibrosis context, red flags, staging and corticosteroid plus antifungal management.

Allergic Rhinitis in Children: A Clinician's Monograph

Clinician reference on pediatric allergic rhinitis — ARIA intermittent vs persistent and mild vs moderate-severe classification, diagnosis, red flags, and stepwise management.

Anaphylaxis in Children: An A-Z Clinical Monograph

Recognise and treat paediatric anaphylaxis — WAO/EAACI diagnostic criteria, red flags, and first-line IM adrenaline 0.01 mg/kg (max 0.3 mg in children), repeated every 5 minutes.